Are there other properties of cochleate technology that provide BDSI with a competitive advantage?
The BDSI cochleate technology can convert intravenous and injectable medications into oral therapeutics. Because the technology is based upon transporting drugs across the intestinal tract and delivering the drug directly to cells, cochleate-delivered drugs demonstrate decreased toxicity and increased efficacy. From an intellectual property position perspective for the cochleate technology, BDSI has exclusive world-wide rights to a broad range of issued US patents providing extensive coverage to cochleate technology formulations and applications. Q: As a new public company, how would you describe BDSI’s first year? A: Within the past year, BDSI has expanded and enhanced its infrastructure in terms of both personnel and technical resources. BDSI is now stronger and more sophisticated in our creative and developmental capabilities. In addition, we have expanded our intellectual property portfolio through the invention of a new composition of matter based upon cochleate technology that sh
